PLX3397 is an investigational drug.
There have been 24 clinical trials for PLX3397.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 20th 2020.
The most common disease conditions in clinical trials are Giant Cell Tumors, Giant Cell Tumor of Tendon Sheath, and Melanoma. The leading clinical trial sponsors are Plexxikon, Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.
There are forty-four US patents protecting this investigational drug and five hundred and thirty-four international patents.